Lexicon Pharmaceuticals (LXRX) Reports Mixed Q4 Results

Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q4 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $343 thousand versus the consensus estimate of $290 thousand.

For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Live Ventures (LIVE) Reports Q3 Loss of $0.34
• MongoDB (MDB) PT Raised at RBC Capital; 'Shares represent an attractive buying opportunity'